微晶羟基磷灰石化合物预防皮质类固醇治疗的慢性活动性肝炎患者的骨质流失。
Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.
作者信息
Stellon A, Davies A, Webb A, Williams R
出版信息
Postgrad Med J. 1985 Sep;61(719):791-6. doi: 10.1136/pgmj.61.719.791.
Abstract
To determine whether microcrystalline hydroxyapatite compound (MCHC) could reduce bone loss or its consequences in patients with chronic active hepatitis (CAH) on corticosteroid therapy, a controlled trial was conducted in 36 such patients over a period of 2 years. Both skeletal symptoms (back pain) and fractures were uncommon during the trial period but both showed non-significant differences in favour of the MCHC group and biochemical investigations were suggestive of a reduction in parathyroid over-activity. Continued reduction in bone mineral content of the radius (photon absorptiometry) was halted in those receiving MCHC and iliac crest bone biopsy showed a non-significant increase in trabecular bone volume. The fall in iliac crest cortical plate thickness was significantly less (P less than 0.025) in the MCHC group and the results overall were consistent with a beneficial effect from MCHC in corticosteroid-induced osteoporosis.
摘要
为了确定微晶羟基磷灰石化合物（MCHC）能否减少接受皮质类固醇治疗的慢性活动性肝炎（CAH）患者的骨质流失或其后果，对36例此类患者进行了为期2年的对照试验。在试验期间，骨骼症状（背痛）和骨折均不常见，但两者均显示出有利于MCHC组的非显著差异，并且生化检查提示甲状旁腺过度活跃有所减轻。接受MCHC的患者桡骨骨矿物质含量（光子吸收法）的持续下降停止，髂嵴骨活检显示小梁骨体积有非显著增加。MCHC组髂嵴皮质板厚度的下降明显较少（P小于0.025），总体结果与MCHC对皮质类固醇诱导的骨质疏松症有有益作用一致。
相似文献
1
Microcrystalline hydroxyapatite compound in prevention of bone loss in corticosteroid-treated patients with chronic active hepatitis.微晶羟基磷灰石化合物预防皮质类固醇治疗的慢性活动性肝炎患者的骨质流失。
Postgrad Med J. 1985 Sep;61(719):791-6. doi: 10.1136/pgmj.61.719.791.
2
Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy.接受维持性皮质类固醇治疗的自身免疫性慢性活动性肝炎患者的骨质流失
Gastroenterology. 1985 Nov;89(5):1078-83. doi: 10.1016/0016-5085(85)90212-4.
3
Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy.
Curr Med Res Opin. 1984;8(10):734-42. doi: 10.1185/03007998409110124.
4
Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis.皮质类固醇治疗的慢性活动性肝炎中的骨组织形态计量学与结构
Gut. 1988 Mar;29(3):378-84. doi: 10.1136/gut.29.3.378.
5
A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss.一项关于泼尼松龙治疗原发性胆汁性肝硬化的为期1年的试点、双盲、对照试验：肝脏状况改善但骨质流失加剧。
Hepatology. 1989 Oct;10(4):420-9. doi: 10.1002/hep.1840100405.
6
Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol.骨病中的钙代谢：微晶羟基磷灰石化合物与二氢速甾醇治疗的效果
J R Soc Med. 1980 Nov;73(11):780-5. doi: 10.1177/014107688007301106.
7
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.磁共振成像测定鲑鱼降钙素对小梁微结构的影响：QUEST研究结果
J Bone Miner Res. 2005 Sep;20(9):1548-61. doi: 10.1359/JBMR.050411. Epub 2005 Apr 27.
8
Backfilling of iliac crest defects with hydroxyapatite-calcium triphosphate biphasic compound: a prospective, randomized computed tomography and patient-based analysis.用羟基磷灰石-磷酸三钙双相化合物填充髂嵴缺损：前瞻性、随机计算机断层扫描和基于患者的分析。
Spine J. 2013 Jan;13(1):54-61. doi: 10.1016/j.spinee.2012.10.019. Epub 2012 Nov 16.
9
Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis.泼尼松龙对乙肝表面抗原阳性慢性活动性肝炎的有害作用。
N Engl J Med. 1981 Feb 12;304(7):380-6. doi: 10.1056/NEJM198102123040702.
10
Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis.皮质类固醇诱导的骨质疏松症中的椎体骨折和皮质骨变化
Osteoporos Int. 2002 Aug;13(8):650-6. doi: 10.1007/s001980200088.
引用本文的文献
1
Acceleration of Bone Fracture Healing through the Use of Bovine Hydroxyapatite or Calcium Lactate Oral and Implant Bovine Hydroxyapatite-Gelatin on Bone Defect Animal Model.通过使用牛羟基磷灰石或乳酸钙口服以及在骨缺损动物模型上植入牛羟基磷灰石-明胶来加速骨折愈合。
Polymers (Basel). 2022 Nov 9;14(22):4812. doi: 10.3390/polym14224812.
2
Glucocorticoid-induced osteoporosis: treatment update and review.糖皮质激素性骨质疏松症：治疗更新与综述。
Ther Adv Musculoskelet Dis. 2009 Apr;1(2):71-85. doi: 10.1177/1759720X09343729.
3
Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound.骨质疏松症的预防：一组接受骨胶原-羟基磷灰石复合物治疗的绝经后妇女的四年随访
Clin Drug Investig. 2007;27(4):227-32. doi: 10.2165/00044011-200727040-00001.
4
US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences.美国和英国糖皮质激素性骨质疏松症指南：异同之处
Curr Rheumatol Rep. 2004 Feb;6(1):66-9. doi: 10.1007/s11926-004-0085-1.
5
Acute changes in serum calcium and parathyroid hormone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers.健康男性志愿者口服五种市售钙盐后血清钙和循环甲状旁腺激素水平的急性变化。
Clin Rheumatol. 1997 May;16(3):249-53. doi: 10.1007/BF02238959.
6
Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females.骨胶原-羟基磷灰石复合物与碳酸钙对骨质疏松女性治疗效果的比较
Osteoporos Int. 1995 Jan;5(1):30-4. doi: 10.1007/BF01623655.
7
Drug-induced rheumatic syndromes. Diagnosis, clinical features and management.药物性风湿综合征。诊断、临床特征与管理
Med Toxicol Adverse Drug Exp. 1989 May-Jun;4(3):199-218. doi: 10.1007/BF03259997.
本文引用的文献
1
Treatment of osteoporosis with fluoride, calcium, and vitamin D.使用氟化物、钙和维生素D治疗骨质疏松症。
Orthop Clin North Am. 1981 Jul;12(3):629-48.
2
Histomorphometric analysis of bone biopsies from the iliac crest of normal British subjects.对正常英国受试者髂嵴骨活检的组织形态计量学分析。
Metab Bone Dis Relat Res. 1982;4(4):231-6. doi: 10.1016/0221-8747(82)90032-7.
3
Radiological patterns of cortical bone modelling in women with chronic liver disease.慢性肝病女性皮质骨建模的放射学模式。
Clin Radiol. 1982 May 3;33(3):313-7. doi: 10.1016/s0009-9260(82)80276-6.
4
The relative merits of various techniques for measuring radiocalcium absorption.
Clin Sci (Lond). 1980 Apr;58(4):287-93. doi: 10.1042/cs0580287.
5
Clinical trial of microcrystalline hydroxyapatite compound ('Ossopan') in the prevention of osteoporosis due to corticosteroid therapy.
Curr Med Res Opin. 1984;8(10):734-42. doi: 10.1185/03007998409110124.
6
Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis.
Am J Clin Nutr. 1982 Sep;36(3):426-30. doi: 10.1093/ajcn/36.3.426.
7
Calcium metabolism in bone disease: effects of treatment with microcrystalline calcium hydroxyapatite compound and dihydrotachysterol.骨病中的钙代谢：微晶羟基磷灰石化合物与二氢速甾醇治疗的效果
J R Soc Med. 1980 Nov;73(11):780-5. doi: 10.1177/014107688007301106.
8
The bone mineral content in the forearm of women with colles' fracture.柯莱斯骨折女性患者前臂的骨矿物质含量。
Acta Orthop Scand. 1974;45(6):836-44. doi: 10.3109/17453677408989694.
Zotero 插件